poorly phrased. There is no standard by which one can compare an odds ratio for CR to a hazard ratio for OS. Given how difficult it has been historically to improve upon the results with MP, and the conflicting results of the various MPT vs MP trials, the clear survival advantage seen with MP-Bortezomib in the VISTA trial is truly remarkable, and by far the most important take-home message. It is not appropriate to directly contrast the results of the E4A03 and VISTA studies (which I agree are both excellent). The contrast I tried to make in the editorial was in the reaction to these trials of stock analysts (whose obtrusive presence at the meeting has recently been noted 16 ), who appear to place an excessively high value on improvements in CR. In my opinion this is not always appropriate, and a more balanced approach is warranted, with better surrogates (for example, molecular CR, suppression of cytogenetic abnormalities) for OS needed. A few studies have reported that AML1-MTG8 expression levels in bone marrow (BM) are 1-to 3-log higher than those in peripheral blood (PB) when detected by quantitative PCR methods in acute myeloid leukemia (AML) with the t(8;21) translocation. 1-3 However, the relationship between BM and PB is retained at any time during the clinical course is unknown. Here we present a patient with t(8;21) AML who demonstrated isolated ovarian relapse after allogeneic BM transplantation (BMT). AML1-MTG8 chimeric transcripts could be repeatedly detected in both BM and PB during the clinical course. Moreover, the AML1-MTG8 expression levels detected by real-time quantitative (RQ)-PCR methods in PB were higher than those in BM before and at the time of the extramedullary relapse (EMR). Thus, we propose that the presence of EMR is responsible for repeated detection of minimal residual disease (MRD) and discuss the clinical significance of different AML1-MTG8 expression levels between BM and PB for the diagnosis of isolated EMR.
7 Hullin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C et al. A few studies have reported that AML1-MTG8 expression levels in bone marrow (BM) are 1-to 3-log higher than those in peripheral blood (PB) when detected by quantitative PCR methods in acute myeloid leukemia (AML) with the t(8;21) translocation. 1-3 However, the relationship between BM and PB is retained at any time during the clinical course is unknown. Here we present a patient with t(8;21) AML who demonstrated isolated ovarian relapse after allogeneic BM transplantation (BMT). AML1-MTG8 chimeric transcripts could be repeatedly detected in both BM and PB during the clinical course. Moreover, the AML1-MTG8 expression levels detected by real-time quantitative (RQ)-PCR methods in PB were higher than those in BM before and at the time of the extramedullary relapse (EMR). Thus, we propose that the presence of EMR is responsible for repeated detection of minimal residual disease (MRD) and discuss the clinical significance of different AML1-MTG8 expression levels between BM and PB for the diagnosis of isolated EMR.
A 22-year-old woman was diagnosed with AML (FrenchAmerican-British (FAB) subtype M2) with thoracic vertebrae involvement in March 1998. Cytogenetic evaluation revealed the t(8;21)(q22;q22) chromosomal translocation. She achieved complete remission (CR) with induction chemotherapy and radiotherapy; however, in December 1998 she had a BM relapse, involving the thoracic vertebrae and the spine. Salvage chemotherapy reduced the total number of leukemic blasts in BM to below 5%. In March 1999, she underwent BMT from her HLA-2-antigen-mismatched/haploidentical sister at Osaka University Hospital. A total of 3.0 Â 10 8 per kg unmanipulated nucleated cells were infused. The transplant protocol consisted of a high dose of cytarabine and cyclophosphamide and total body irradiation (12 Gy), followed by a short course of methotrexate, tacrolimus and methylprednisolone (2 mg/kg) for graft-versus-host disease (GVHD) prophylaxis. The patient achieved an absolute neutrophil count above 0.5 Â 10 9 per liter on day 20. The last platelet transfusion was performed on day 125. CR and complete donor chimerism was confirmed by a BM examination on day 24. No acute GVHD developed.
We sequentially measured AML1-MTG8 expression levels using RQ-PCR methods during the clinical course as previously described.
4 AML1-MTG8 levels in BM stayed below 1.0 Â 10 À5 after BMT, but increased to 3.8 Â 10 À5 on day 96. Thereafter, AML1-MTG8 levels in BM and PB were monitored biweekly and weekly, respectively. Whereas AML1-MTG8 levels in BM and PB showed parallel movement, those in PB were constantly over 2.0 Â 10 À4 and were higher than those in BM. Because a BM examination still revealed CR, we suspected a regrowth of leukemia cells in the patient and performed a systemic examination. Computed tomography scans of the pelvis revealed little ascites in the patient on day 109, but an enlargement of the left ovary with a diameter of 5 cm with moderate ascites on day 158 (Figure 1 ). The ovarian tumor was diagnosed as EMR due to the contamination of t(8;21)-positive leukemia cells in ascites by culdocentesis.
As tacrolimus and prednisolone were tapered rather rapidly for induction of a graft-versus-leukemia effect, skin GVHD developed on day 170. Following increase in tacrolimus and prednisolone, the skin rash disappeared in about a week, followed by shrinkage of the tumor to a diameter of 2.5 cm and disappearance of the ascites on day 185. AML1-MTG8 levels in both BM and PB decreased to below 1.0 Â 10 À5 on day 187; however, the levels increased again with some fluctuations. Magnetic resonance imaging of the pelvis on day 262 showed enlargement of the left ovarian tumor again. Because BM was still present in CR, bilateral salpingo-oophorectomy was performed on day 319. The bilateral ovaries appeared to be involved, making complete resection impossible due to tight adhesion with surrounding tissues. AML1-MTG8 levels were highest in the BM greater than those in PB, when morphologic BM relapse occurred on day 355 (Figure 1) . Despite chemotherapy and donor lymphocyte infusion, the patient died of renal failure due to obstruction of the bilateral ureters by abdominal mass on day 474.
EMR of leukemia after transplant occurs in diverse sites such as the central nervous system and testis, which makes an early diagnosis difficult. One feasible approach to overcome this problem would be monitoring MRD that is involved in BM. 5, 6 In the present case, continuous detection of AML1-MTG8 chimeric transcripts not only in BM, but also in PB was quite helpful in detecting the presence of EMR. So far nested PCR detection of AML1-MTG8 chimeric transcripts in BM and PB have not been the indicators of subsequent relapse in t(8;21) AML after BMT. 7 Meanwhile, recent studies using quantitative PCR methods reported that there is a threshold of AML1-MTG8 expression levels at which subsequent relapse occurs. 1, 8, 9 Therefore, frequent monitoring of AML1-MTG8 expression levels or systemic screening for extramedullary disease should be considered, especially as AML1-MTG8 chimeric transcripts continued to be detected despite CR.
Interestingly, the AML1-MTG8 levels in BM and PB showed reversal between day 112 and 179, suggesting that t(8;21)-positive leukemia cells originated from extramedullary disease were constantly present in PB, rather than in BM. Given that this unusual relationship returned to the original state at the time of BM relapse, higher AML1-MTG8 expression levels in PB compared to BM suggest a sign of isolated EMR. However, further studies are required to determine whether screening of PB is superior to BM for early detection of isolated EMR by PCR-based monitoring AML1-MTG8 expression levels. Figure 1a ). This impaired Ca o S activity was not due to decreased stores of Ca i 2 þ in the endoplasmic reticulum, as the Ca 2 þ ATPase inhibitor, thapsigargin, was able to mobilize Ca i 2 þ in these cells (not shown). While normal B-cells mobilized Ca i 2 þ in response to as little as 250 mM CaCl 2 , Ca o 2 þ non-responder CLL cells remained insensitive to doses as high as 1.5 mM (above which, calcium was toxic) (not shown). These results suggested that the defective responses to Ca o 2 þ were not due to reduced expression or 
